U.S., March 28 -- ClinicalTrials.gov registry received information related to the study (NCT07495384) titled 'Efficacy and Safety of CapsuleX Combined With Cisplatin in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Arm Prospective Clinical Study' on March 21.

Brief Summary: This trial was designed as a single-arm, open-label, prospective clinical trial to evaluate the efficacy (ORR) and safety (AE incidence) of CapsuleX in combination with cisplatin for platinum-resistant recurrent ovarian cancer (PROC).

Study Start Date: Jan. 17, 2025

Study Type: INTERVENTIONAL

Condition: Recurrent Ovarian Cancer Platinum Resistance

Intervention: DRUG: CapsuleX

CapsuleX Combined with Cisplatin

Recruitment Status: RECRUITING

Sponsor: The F...